» Articles » PMID: 37964279

Insights into the Regulatory Role of RNA Methylation Modifications in Glioma

Overview
Journal J Transl Med
Publisher Biomed Central
Date 2023 Nov 14
PMID 37964279
Authors
Affiliations
Soon will be listed here.
Abstract

Epitranscriptomic abnormalities, which are highly prevalent in primary central nervous system malignancies, have been identified as crucial contributors to the development and progression of gliomas. RNA epitranscriptomic modifications, particularly the reversible modification methylation, have been observed throughout the RNA cycle. Epitranscriptomic modifications, which regulate RNA transcription and translation, have profound biological implications. These modifications are associated with the development of several cancer types. Notably, three main protein types-writers, erasers, and readers, in conjunction with other related proteins, mediate these epitranscriptomic changes. This review primarily focuses on the role of recently identified RNA methylation modifications in gliomas, such as N6-methyladenosine (m6A), 5-methylcytosine (m5C), N7-methylguanosine (m7G), and N1-methyladenosine (m1A). We delved into their corresponding writers, erasers, readers, and related binding proteins to propose new approaches and prognostic indicators for patients with glioma.

Citing Articles

Inhibitor of Growth Proteins: Epigenetic Regulators Shaping Neurobiology.

Xu Z, Xu H, Shi J, Liu R, Li X, Liu S Biomolecules. 2025; 15(2).

PMID: 40001584 PMC: 11852745. DOI: 10.3390/biom15020281.


The role of m5C RNA modification in cancer development and therapy.

Yu L, Xu H, Xiong H, Yang C, Wu Y, Zhang Q Heliyon. 2024; 10(19):e38660.

PMID: 39444404 PMC: 11497397. DOI: 10.1016/j.heliyon.2024.e38660.


Influence of RNA Methylation on Cancerous Cells: A Prospective Approach for Alteration of In Vivo Cellular Composition.

Rupareliya M, Shende P Adv Exp Med Biol. 2024; 1474():79-103.

PMID: 39259424 DOI: 10.1007/5584_2024_820.

References
1.
Xi Z, Wang P, Xue Y, Shang C, Liu X, Ma J . Overexpression of miR-29a reduces the oncogenic properties of glioblastoma stem cells by downregulating Quaking gene isoform 6. Oncotarget. 2017; 8(15):24949-24963. PMC: 5421901. DOI: 10.18632/oncotarget.15327. View

2.
Huff S, Kummetha I, Zhang L, Wang L, Bray W, Yin J . Rational Design and Optimization of mA-RNA Demethylase FTO Inhibitors as Anticancer Agents. J Med Chem. 2022; 65(16):10920-10937. PMC: 9421652. DOI: 10.1021/acs.jmedchem.1c02075. View

3.
Babic I, Anderson E, Tanaka K, Guo D, Masui K, Li B . EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. Cell Metab. 2013; 17(6):1000-1008. PMC: 3679227. DOI: 10.1016/j.cmet.2013.04.013. View

4.
Hsu P, Zhu Y, Ma H, Guo Y, Shi X, Liu Y . Ythdc2 is an N-methyladenosine binding protein that regulates mammalian spermatogenesis. Cell Res. 2017; 27(9):1115-1127. PMC: 5587856. DOI: 10.1038/cr.2017.99. View

5.
Liao H, Gaur A, McConie H, Shekar A, Wang K, Chang J . Human NOP2/NSUN1 regulates ribosome biogenesis through non-catalytic complex formation with box C/D snoRNPs. Nucleic Acids Res. 2022; 50(18):10695-10716. PMC: 9561284. DOI: 10.1093/nar/gkac817. View